MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge numerous intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although among the list of https://harrisonw000iuf3.corpfinwiki.com/user